Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/-
ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1
year following completion of standard bi-/tri-modality therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins